首页> Expert review of clinical immunology> Emerging therapy options for IgG4-related disease.

Emerging therapy options for IgG4-related disease.

导出 LinkOut

翻译打印收藏纠错

第一作者： Marco,Lanzillotta

第一单位： Università Vita-Salute San Raffaele, IRCCS San Raffaele Scientific Institute, Milan, Italy.;Unit of Immunology, Rheumatology, Allergy and Rare Diseases (Unirar), IRCCS San Raffaele Scientific Institute, ss Milan, Italy.

作者： Marco,Lanzillotta ^[1] ; Andreu,Fernàndez-Codina ^[2] ; Emma,Culver ^[3] ; Mikael,Ebbo ^[4] ; Fernando,Martinez-Valle ^[5] ; Nicolas,Schleinitz ^[4] ; Emanuel,Della-Torre ^[1]

作者单位： Università Vita-Salute San Raffaele, IRCCS San Raffaele Scientific Institute, Milan, Italy.;Unit of Immunology, Rheumatology, Allergy and Rare Diseases (Unirar), IRCCS San Raffaele Scientific Institute, ss Milan, Italy. ^[1] Internal Medicine Department, Hospital Universitari Vall d'Hebron, Barcelona, Spain.;Rheumatology Division and General Internal Medicine division-Windsor Campus, Western University, 268 Grosvenor St, D2-191, Rheumatology Centre, St. Joseph´s Health Care, London, Ontario, Canada. ^[2] Translational Gastroenterology Unit, University of Oxford, Oxford,UK.;Hepatology, Oxford University Hospitals NHS Foundation Trust, Oxford, UK. ^[3] Département De Médecine Interne, Centre De Référence Constitutif Des Cytopénies Auto-immunes De L'adulte (CERECAI), Hôpital De La Timone, Aix-Marseille Université, Assistance publique-Hôpitaux De Marseille, Marseille, France. ^[4] Internal Medicine Department, Hospital Universitari Vall d'Hebron, Barcelona, Spain. ^[5]

关键词 Abatacept biologic corticosteroids fibrosis glucocorticoids igg4 igg4-related disease rituximab therapy treatment

医学主题词糖皮质激素类(Glucocorticoids);人类(Humans);免疫球蛋白G(Immunoglobulin G);免疫抑制剂(Immunosuppressive Agents);复发(Recurrence)

DOI 10.1080/1744666X.2021.1902310

PMID 33689549

发布时间 2022-03-01

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交